RT Journal Article
SR Electronic
T1 Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.29.21259427
DO 10.1101/2021.06.29.21259427
A1 ,
A1 ,
A1 Bégin, Philippe
A1 Callum, Jeannie
A1 Jamula, Erin
A1 Cook, Richard
A1 Heddle, Nancy M.
A1 Tinmouth, Alan
A1 Zeller, Michelle P.
A1 Beaudoin-Bussières, Guillaume
A1 Amorim, Luiz
A1 Bazin, Renée
A1 Loftsgard, Kent Cadogan
A1 Carl, Richard
A1 Chassé, Michaël
A1 Cushing, Melissa M.
A1 Daneman, Nick
A1 Devine, Dana V.
A1 Dumaresq, Jeannot
A1 Fergusson, Dean A.
A1 Gabe, Caroline
A1 Glesby, Marshall J.
A1 Li, Na
A1 Liu, Yang
A1 McGeer, Allison
A1 Robitaille, Nancy
A1 Sachais, Bruce S.
A1 Scales, Damon C.
A1 Schwartz, Lisa
A1 Shehata, Nadine
A1 Turgeon, Alexis F.
A1 Wood, Heidi
A1 Zarychanski, Ryan
A1 Finzi, Andrés
A1 Arnold, Donald M.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259427.abstract
AB The efficacy of convalescent plasma for COVID-19 is unclear. While most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content may influence patient outcomes.We conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 days of respiratory symptom onset. Patients were allocated 2:1 to 500 mL of convalescent plasma or standard of care. The composite primary outcome was intubation or death by 30 days. The effect of convalescent plasma antibodies on the primary outcome was assessed by logistic regression.The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility. 940 patients were randomized and 921 patients were included in the intent-to-treat analysis. Intubation or death occurred in 199/614 (32.4%) in the convalescent plasma arm and 86/307 (28.0%) in the standard of care arm; relative risk (RR) 1.16 (95% confidence interval (CI) 0.94-1.43; p=0.18). Patients in the convalescent plasma arm had more serious adverse events (33.4% vs. 26.4%; RR=1.27, 95% CI 1.02-1.57, p=0.034). The antibody content significantly modulated the therapeutic effect of convalescent plasma. In multivariate analysis, each standard log increase in neutralization or antibody-dependent cellular cytotoxicity independently reduced the potential harmful effect of plasma (OR=0.74; 0.57-0.95 and OR=0.66; 0.50-0.87, respectively), while IgG against the full transmembrane Spike protein increased it (OR=1.53, 95% CI 1.14-2.05).Convalescent plasma did not reduce the risk of intubation or death at 30 days among hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavourable antibody profiles may be associated with worse clinical outcomes compared to standard care.Trial registration CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1); NCT04348656; https://www.clinicaltrials.gov/ct2/show/NCT04348656Competing Interest StatementPB reports payments to his institution from Canadian Institutes of Health Research, Ministere de l'economie et de l'innovation du Quebec, Fondation du CHU Sainte-Justine, Fondation du CHUM, and Fonds de Recherche du Quebec en Sante; JC reports research grants from Canadian Institutes of Health Research, University of Toronto, Sunnybrook Health Sciences Centre, and Canadian Blood Services; NMH reports research project funding unrelated to this study from Canadian Institutes of Health Research and Canadian Blood Services, honorarium for educational events unrelated to this study from CSL Behring Canada, and participation on a Data Safety Monitoring Board or Advisory Board for Canadian Blood Services (Scientific Advisory Committee); MPZ reports consulting fees from Canadian Blood Services in her role as a Medical Officer but receives no direct benefit from the study results; GBB reports a grant from Canadian Institutes of Health Research for Masters students; MMC reports consulting fees from Octapharma, participation in a data safety monitoring board or advisory board for Cerus and Haemonetics, and receipt of equipment, materials, drugs, medical writing, gifts or other services by her institution from Cerus; ND reports grants from AFP Innovation Fund Award Sunnybrook Health Sciences Centre, and University of Toronto; MJG reports payments to his institution from Regeneron, consulting fees from Regeneron and ReAlta Life Sciences, and participation on a Data Safety Monitoring Board or Advisory Board for Enzychem and Sobi; BSS reports employment by New York Blood Centre (but receiving no direct benefit from study participation); LS reports a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid (Member of the Ontario Bioethics Table for COVID-19); NS reports payment to her institution from the MSH Foundation for CONCOR; AF reports funding from Fondation du CHUM, Ministere de l'economie et de l'Innovation du Quebec, and Canadian Institutes of Health Research. All other authors declare no competing interests.Clinical TrialNCT04348656Clinical Protocols https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05235-3 Funding StatementFunding for the study was provided by Canadian Institutes of Health Research - COVID-19 May 2020 Rapid Research Funding Opportunity - Operating Grant; Ontario COVID-19 Rapid Research Fund; Toronto COVID-19 Action Initiative 2020 (University of Toronto); University Health Network Emergent Access Innovation Fund; University Health Academic Health Science Centre Alternative Funding Plan (Sunnybrook Health Sciences Centre); Ministere de l'Economie et de l'Innovation (Quebec);  Saskatchewan Ministry of Health; University of Alberta Hospital Foundation; Alberta Health Services COVID-19 Foundation Competition; Sunnybrook Health Sciences Centre Foundation; Fondations CHU Ste-Justine; Fondation du CHUM; The Ottawa Hospital Academic Medical Organization; The Ottawa Hospital Foundation COVID-19 Research Fund; Sinai Health System Foundation and McMaster University. These did not have any role in the writing of the manuscript or the decision to submit it for publication. The authors did not receive payments from any pharmaceutical company or other agency to write this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Clinical Trials Ontario (Research Ethics Board of Record: Sunnybrook Health Sciences Centre), project #2159; the Quebec Ministry of Health and Social Services multicenter ethics review (REB of Record: Comite d'ethique de la recherche du CHU Sainte-Justine), project #MP-21-2020-2863; the Weil Cornell Medicine General Institutional Review Board, protocol number 20-04021981; as well as the Comissao Nacional de Etica em Pesquisa, approval 4.305.792.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified individual patient data with the data dictionary that underlie the reported results will be made available upon request if approved by the CONCOR-1 Steering Committee. Proposals for access should be sent to arnold@mcmaster.ca.